Tocagen – $98 Million IPO

San Diego – April 20, 2017 – Cooley advised Tocagen on its $97.8 million initial public offering of 9,775,000 shares of common stock.

San Diego-based Tocagen, which trades on The NASDAQ Global Select Market as “TOCA,” is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Fred Muto Senior Counsel, San Diego
Ken Rollins Partner, San Diego
Karen Anderson Partner, San Diego
Wade Andrews Associate, San Diego
Matt Robbins Associate, San Diego
Jessica Wade Senior Paralegal, San Diego
Natasha Leskovsek Partner, Washington, DC
Wendy Goldstein Partner, New York
Phil Mitchell Partner, New York
Megan Arthur Schilling Partner, San Diego
Dani Nazemian Associate, San Diego
Susan Cooper Philpot Partner, San Francisco